The controvertible role of kava (Piper methysticum G. Foster) an anxiolytic herb, on toxic hepatitis

Revista Brasileira de Farmacognosia

Volumn 17, Issue 3, 2007, Pages 448-454

  Amorim, Maria F D ^a   Diniz, Margareth F F M ^a   Arauj́o, Maria S T ^a   Pita, João C L R ^a   Dantas, Jadson G ^a   Ramalho, Josué A ^a   Xavier, Aline L ^a   Palomaro, Thayse V ^a   Júnior, Nelson L B ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Hepatitis; Kava; Piper methysticum; Piperaceae; Toxic

Indexed keywords

EID: 35248816024     PISSN: 0102695X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0102-695X2007000300020     Document Type: Review

References (65)

1. Abebe W 2002. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 27: 391-401.
2. AFSSAPS 2006. Agence Française de Securité Sanitaire des Produits de Santé. Accessed June 20, 2006, at http://agmed.sante.gouv. fr/htm/alertes/filalert/deciskav.pdf.
3. Amorim MFD, Amorim WPD, Duques P, Amorim PD, Vasconcelos JR 2005. Flutamide-induced hepatotoxicity during treatment of acne - A case report. An Bras Dermatol 80: 381-384.
4. Andreatini R, Boerngen-Lacerda R, Filho DZ 2001. Pharmacological treatment of generalized anxiety disorder: future perspectives. Rev Bras Psiquiatr 23: 233-242.
5. Anke J, Ramzan I 2004. Kava hepatotoxicity: Are we any closer to the truth? Planta Med 70: 193-196.
6. ANVISA 2006. Agência Nacional de Vigilância Sanitária - Brasil (Legislaçào - Resoluções). Accessed Mai 4, 2006, at http://anvisa.gov.br.
7. Bilia AR, Gallori S, Vincieri FF 2002. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci 70: 2581-2597.
8. Bilia AR, Scalise L, Bergonzi MC, Vincieri FF 2004. Analisis of kavalactones from Piper methysticum. J Chromatogr B 812: 203-204.
9. Blendis L 2005. Chaos in hepatology: do we know what our patients are taking?. Gastroenterol 128: 240.
10. Bogusz MJ, Al Tufail M, Hassan H 2002. How natural are "natural herbal remedies"? A Saudi perspective. Adverse Drug React Toxicol Rev 21: 219-229.
11. Clouatre DL 2004. Kava kava: examining new reports of toxicity. Toxicol Lett 150: 85-96.
12. Clough AR, Bailie RS, Currie B 2003. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol-Clin Toxic 41: 821-829.
13. Cordeiro CHG, Chung MC, Sacramento LVS 2005. Interações medicamentosas de fitoterápicos e fãrmacos: Hypericum perforatum e Piper methysticum. Rev Bras Farmacogn 13: 272-278.
14. Côté CS, Kor C, Cohen J, Auclari K 2004. Composition and biological activity of traditional and commercial kava extracts. Biol Biophy Res Comm 322: 147-152.
15. De Smet PAGM 2002. Drug Therapy: herbal remedies. N Engl J Med 347: 2046-2056.
16. Denham A, McIntyre M, Whitehouse J 2002. Kava - the unfolding story: report on a work-in-progress. J Altern Complem Med 8: 237-263.
17. Donadio V, Bonsi P, Zele I, Monari L, Liguori R, Vetrugno R, Albani F, Montagna P 2000. Myoglobinuria after ingestion of extracts of guarana, Ginkgo biloba and kava. Neural Sci 21: 124.
18. Dufour JF, St-Pierre MV 2002. Phytotherapeutic drugs in gastroenterology and hepatology. Ther Umsch 59: 313-316.
19. Ernst E 2000. Adverse effects of herbal drugs in dermatology. Brit J Dermatol 43: 923.
20. Ernst E 2002. Safety concerns about kava. Lancet 359: 1865.
21. Ernst E, Pittler MH 2003. Systematic review: hepatotoxic events associated with herbal medicinal products. Alim Pharm Ther 18: 451-471.
22. Feltenstein MW, Lambdin LC, Ganzera M, Ranjith H, Dharmaratne W, Nanayakkara NP, Khan IA, Sufka KJ 2003. Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social-separation- stress procedure. Phytother Res 17: 210-216.
23. Food and Drug Administration (FDA) 2002. Kava-containing dietary supplements may be associated with severe liver injury. Center for Food Safety and Applied Nutrition, U. S. Food and Drug Administration, Dietary Supplements.
24. Fugh-Berman A, Ernst E 2001. Herb-drug interactions: Review and assessment of report reliability. Brit J Clin Pharmacol 52: 587-595.
25. Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PW 2003. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 178: 442-443.
26. Grunze H, Walder J 1999. Kawain limits excitation in CA 1 pyramidal neurons of rats by modulating ionic currents and attenuating excitatory synaptic transmission. Hum Psychopharmacol Clin Exp 14: 63-66.
27. Hentze H, Gantner F, Kolb SA, Wendel A 2000. Depletion of hepatic glutathione prevents death receptor-dependent apoptotic and necrotic liver injury in mice. Am J Path 156: 2045-2056.
28. Humberston CL, Akhtar J, Krenzelok EP 2003. Acute hepatitis induced by kava kava. J Toxicol-Clin Toxic 41: 109-113.
29. Johnson BM, Qiu HX, Zhang S, Zhang F, Burdette JE, Yu L, Boltom JL, Breemen RB 2003. Identification of novel electrophilic metabolites of Piper methysticum Forst (Kava). Chem Res Toxicol 16: 733-740.
30. Kaplowitz N 2001. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 33: 308-310.
31. Kaplowitz N 2002. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 22: 137-144.
32. Kraft M, Spahn TW, Menzel J, Senninger N, Dietl KH, Herbst H, Domschke W, Lerch MM 2001. Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. Dtsch Med Wochenschr 126: 970-972.
33. Lebot V, Levesque J 1989. The origin and distribution of kava (Piper methysticum Frost. f. and Piper wichmanii C. DC., Piperaceae) a phytochemical approach. Allertonia 5: 223-281.
34. Lee WM 2003. Drug-induced hepatotoxicity. N Engl J Med 349: 474-485.
35. Lehrl S 2004. Clinical efficacy of kava extract WSR 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disorders 78: 101-110.
36. Lekehal M, Pessayre D, Lereau JM, Moulis C, Fouraste I, Fau D 1996. Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A Depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 24: 212-2188.
37. Maddrey WC 2003. Clinicophathological patterns of drug-induced liver disease. In: Kaplowitz N, Deleve LD. Drug induced Liver Disease. New York: Marcel Dekker, Inc. 724p.
38. Maddrey WC 2005. Drug-induced hepatotoxicity. J Clin Gastroenterol 39(S2): 83-89.
39. +-channels in rat CA1 hippocampal neurons. Neuroscience 81: 345-351.
40. Mathews JM, Etheridge AS, Black SR 2002. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 30: 1153-1157.
41. MCA 2005. Medicines Control Agency. Investigation of Kava Kava Leads to Ban Following Voluntary Withdrawal. December 20, 2002. Accessed October 12, 2005, at http://www.mca.gov.uk/whatsnew/pressreleases/Kava211202.pdf.
42. Meseguer E, Taboada R, Sánchez V, Mena MA, Campos V, Yébenes JG 2002. Life-threatening parkinsonism induced by kava-kava. Mov Disorders 17: 195-196.
43. Miller LG 1998. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158: 2200-2211.
44. Musch E, Chrissafidou A, Malek M 2006. Acute hepatitis due to kava-kava and St John's Wort: an immune-mediated mechanism? Dtsch Med Wochenschr 131: 1214-1217.
45. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ 1981. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245.
46. Navarro VJ, Senior JR 2006. Drug-related Hepatotoxicity. N Engl J Med 354: 131-739.
47. Nerurkar PV, Dragull K, Tang CS 2004. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol Sci 79: 106-111.
48. Pauwels A, Thierman-Duffaud D, Azanowsky JM, Loiseau D, Biour M, Levy VG 1992. Acute hepatitis caused by wild germander. Hepatotoxicity of herbal remedies. Two cases. Gastroenterol Clin Biol 16: 92-95.
49. Pittler MH, Ernst E 2000. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 20: 84-89.
50. Pittler MH, Ernst E 2003. Kava extract for treating anxiety. Cochrane Database Syst Rev 1: CD003383.
51. Russmann S, Lauterburg BH, Helbling A 2001. Kava hepatotoxicity. Ann Intern Med 135: 68-69.
52. Russmann S, Barguil Y, Cabalion P, Kritsanida M, Duhet D, Lauterburg B 2003. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol 15: 1033-1036.
53. Schmidt M 2006. Is kava really hepatotoxic? Accessed: June 29, 2006, at http://www.taxtyranny.ca/images/HTML/KavaKava/Articles/KavaReview.pdf.
54. Sibon I, Rosier E, Orgogozo JM 2002. Meningismus after taking kava-kava. Rev Neural 158: 1205-1296.
55. Singh YN, Devkota AK 2003. Aqueous kava extracts do not affect liver function tests in rats. Planta Med 69: 496-499.
56. Siméoni P, Lebot V 2002. Identification of factors determining kava lactone content and chemotype in kava (Piper methysticum Forst, f.). Biochem Syst Ecol 30: 413-424.
57. Spinella M 2001. Herbal medicines and epilepsy: The potential for benefit and adverse effects. Epilepsy Behav 2: 524-532.
58. Stevinson C, Alyson H, Ernst E 2002. A Systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety 25: 251-261.
59. Stickel F, Baumüller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK, Schuppan D 2003. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 39: 62-67.
60. Stickel F, Patsenker E, Schuppan D 2005. Herbal hepatotoxicity. J Hepatol 43: 901-910.
61. Teschke R, Gaus W, Loew D 2003. Kava extracts: Safety and risks including rare hepatotoxicity. Phytomedicine 10: 440-446.
62. Wheatley D 2005. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. J Psychopharmacol 4: 414-421.
63. Whitton PA, Lau A, Salisbury A, Whitehouse JS, Evans CS 2003. Kava lactones and the kava-kava controversy. Phytochemistry 64: 673-679.
64. Wilkinson GR 2005. Drug metabolism and variability among patients in drug response. N Engl J Med 352: 2211-2221.
65. Yamada M, Kohno T, Asakawa Y 2003. Isolation and synthesis of TNF-alpha release inhibitors from Fijian kawa (Piper methysticum). Phytomedicine 10: 309-317.